home / stock / okyo / okyo quote
Last: | $1.21 |
---|---|
Change Percent: | 1.61% |
Open: | $1.22 |
Close: | $1.21 |
High: | $1.22 |
Low: | $1.19 |
Volume: | 7,023 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.21 | $1.22 | $1.21 | $1.22 | $1.19 | 7,023 | 07-02-2024 |
$1.24 | $1.15 | $1.24 | $1.28 | $1.15 | 6,667 | 07-01-2024 |
$1.19 | $1.12 | $1.19 | $1.21 | $1.12 | 5,188 | 06-28-2024 |
$1.1308 | $1.13 | $1.1308 | $1.155 | $1.11 | 12,260 | 06-27-2024 |
$1.18 | $1.19 | $1.18 | $1.19 | $1.1113 | 2,804 | 06-26-2024 |
$1.16 | $1.2 | $1.16 | $1.22 | $1.09 | 23,611 | 06-25-2024 |
$1.21 | $1.23 | $1.21 | $1.23 | $1.21 | 5,184 | 06-24-2024 |
$1.25 | $1.23 | $1.25 | $1.26 | $1.22 | 3,191 | 06-21-2024 |
$1.24 | $1.24 | $1.24 | $1.285 | $1.23 | 4,924 | 06-20-2024 |
$1.28 | $1.3799 | $1.28 | $1.3799 | $1.26 | 3,219 | 06-19-2024 |
$1.28 | $1.3799 | $1.28 | $1.3799 | $1.26 | 3,219 | 06-18-2024 |
$1.3 | $1.28 | $1.3 | $1.335 | $1.28 | 5,898 | 06-17-2024 |
$1.3081 | $1.3 | $1.3081 | $1.33 | $1.28 | 2,527 | 06-14-2024 |
$1.3601 | $1.34 | $1.3601 | $1.3601 | $1.24 | 7,967 | 06-13-2024 |
$1.3199 | $1.33 | $1.3199 | $1.48 | $1.29 | 46,440 | 06-12-2024 |
$1.4131 | $1.34 | $1.4131 | $1.4797 | $1.33 | 14,794 | 06-11-2024 |
$1.3589 | $1.39 | $1.3589 | $1.39 | $1.3 | 3,625 | 06-10-2024 |
$1.27 | $1.38 | $1.27 | $1.38 | $1.2299 | 8,477 | 06-07-2024 |
$1.34 | $1.3825 | $1.34 | $1.41 | $1.34 | 824 | 06-06-2024 |
$1.3306 | $1.4298 | $1.3306 | $1.4298 | $1.3306 | 10,198 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...